文献速递肿瘤 PET/CT甲状腺核医学

五种不同PET放射性药物检测复发性甲状腺髓样癌的比较:一项网络Meta分析

Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2020-01-01

该网络Meta分析纳入14项直接比较研究、共306例患者,比较5种PET放射性药物检测复发性甲状腺髓样癌的表现。患者分析和病灶分析均显示F-DOPA PET检出率显著高于FDG PET,且F-DOPA累积排序曲线下面积值最高。

要点

  • 患者分析中F-DOPA PET检出率显著高于FDG PET(OR 2.44,95%CI 1.4-4.31)。
  • 病灶分析中F-DOPA PET检出率显著高于FDG PET(OR 5.74,95%CI 1.65-23.4)。
  • 无论血清降钙素或CEA水平及降钙素倍增时间如何,F-DOPA的累积排序曲线下面积值均最高。

核心结论

  • 该网络Meta分析结果表明,无论血清降钙素或CEA水平及降钙素倍增时间如何,F-DOPA PET在患者分析和病灶分析中检测复发性甲状腺髓样癌均显示最佳表现。

研究设计与样本

  • 检索PubMed和EMBASE中评估PET或PET/CT检测复发性甲状腺髓样癌表现的研究。
  • 对2种或以上PET放射性药物直接比较研究进行网络Meta分析,共纳入14项直接比较研究、306例患者,涉及5种PET放射性药物(F-FDG、F-DOPA、Ga-生长抑素类似物、3-O-甲基-6-[F]氟-DOPA和C-甲硫氨酸)。
  • 分别进行患者分析和病灶分析,并按血清降钙素或CEA水平阈值及降钙素倍增时间分层。
  • 通过检查直接与间接治疗效应的一致性评估一致性,通过漏斗图不对称检验评估发表偏倚。
  • 获取累积排序曲线下面积值以计算每种PET模态成为最有效诊断方法的概率。

主要发现

  • 患者分析中F-DOPA PET检出率显著高于FDG PET(OR 2.44,95%CI 1.4-4.31)。
  • 病灶分析中F-DOPA PET检出率显著高于FDG PET(OR 5.74,95%CI 1.65-23.4)。
  • 无论血清降钙素或CEA水平及降钙素倍增时间如何,F-DOPA在患者分析和病灶分析中的累积排序曲线下面积值均为最高。

关键数值与推荐

  • 患者分析:F-DOPA PET对比FDG PET的OR为2.44(95%CI 1.4-4.31)。
  • 病灶分析:F-DOPA PET对比FDG PET的OR为5.74(95%CI 1.65-23.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study is to investigate and compare the performance of different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma (MTC) by performing a network meta-analysis (NMA) using direct comparison studies with 2 or more PET radiopharmaceuticals. METHODS: PubMed and EMBASE were searched for the studies evaluating the performance of PET or PET/CT for the detection of recurrent MTC. The NMA was performed for different PET radiopharmaceuticals in both patient- and lesion-based analyses and with a threshold of serum calcitonin or carcinoembryonic antigen (CEA) levels and calcitonin doubling time. The consistency was evaluated by examining the agreement between direct and indirect treatment effects, and publication bias was assessed by funnel plot asymmetry tests. The surface under the cumulative ranking curve values were obtained to calculate the probability of each PET modality being the most effective diagnostic method. RESULTS: A total of 306 patients from 14 direct comparison studies using 5 different PET radiopharmaceuticals (F-FDG, F-DOPA, Ga-somatostatin analogs, 3-O-methyl-6-[F]fluoro-DOPA, and C-methionine) for the detection of recurrent MTC was included. The detection rate of F-DOPA PET was significantly higher than that of FDG PET in both patient- and lesion-based analyses (patient-based analysis: odds ratio, 2.44; 95% confidence interval, 1.4-4.31; lesion-based analysis: odds ratio, 5.74; 95% confidence interval, 1.65-23.4). Among all PET radiopharmaceuticals, F-DOPA showed the highest surface under the cumulative ranking curve value in both patient- and lesion-based analyses regardless of serum calcitonin or CEA levels and calcitonin doubling time. CONCLUSIONS: The results from this NMA indicate that F-DOPA PET clearly showed a best performance for the detection of recurrent MTC in both patient- and lesion-based analyses regardless of serum calcitonin or CEA levels and calcitonin doubling time.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lee SW, Shim SR, Jeong SY, et al. Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis. Clin Nucl Med. 2020. PMID: 32049723. doi:10.1097/RLU.0000000000002940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。